Theragen Bio and Korea University Ansan Hospital (KUAH) said they would team up to utilize precision genomic data.

In a memorandum of understanding (MOU) signed between the two organizations last Thursday, Theragen Bio will leverage its over 10 years of expertise and technology to generate and provide high-quality genomic information. 

KUAH plans to utilize this data for tumor research.

They will also collaborate on cutting-edge precision medical services such as single-cell genome and spatial transcriptome analysis. 

Additionally, the two entities will identify and undertake joint research projects.

"The importance of securing high-quality genomic information data using the latest technologies in cancer research continues to increase," Theragen Bio research center head Paik Soon-myung said. "The high-quality data provided by the company will contribute to cancer research at KUAH."

KUAH Deputy Director of Research Professor Lee Ju-han also said, "It is important to secure the latest data to realize precision medicine."

Together with Theragen Bio, the hospital will discover and collaborate on relevant research projects and strive to advance cancer research at the hospital.